uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
02 nov. 2021 07h05 HE
|
uniQure Inc.
~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~ ~ Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02,...
uniQure to Participate in Upcoming Industry Conferences in November
01 nov. 2021 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
25 oct. 2021 07h05 HE
|
uniQure Inc.
~ Completed 78-week follow-up for hemophilia B pivotal study, with top-line data expected by year-end 2021 ~ ~ Enrolled 14 patients to date in Phase 1/2 clinical trial of AMT-130 in Huntington’s...
uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
21 oct. 2021 09h30 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
19 oct. 2021 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in October
30 sept. 2021 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure to Participate in Multiple Upcoming Industry Conferences in September
07 sept. 2021 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Sept. 07, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
30 août 2021 07h05 HE
|
uniQure Inc.
~ No Significant Safety Concerns Observed Across a Total of 14 Completed Procedures ~ ~ Full Study Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands,...
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
26 juil. 2021 07h05 HE
|
uniQure Inc.
~ Expanded gene therapy pipeline with four new research programs and announced acquisitionof Corlieve Therapeutics ~ ~ Presented positive 52-week data from HOPE-B pivotal study demonstrating...
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
02 juil. 2021 09h00 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, July 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...